Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

M. J. Reike; M. A. Ingersoll; D. C. Müller; T. C.M. Zuiverloon; T. Strandgaard; A. M. Kamat; S. B. Williams; R. Seiler; T. Todenhöfer; L. Dyrskjøt; R. Nawroth; P. Goebell; B. Schmitz-Dräger; J. P. Sfakianos; J. Meeks; A. Horowitz; P. C. Black

doi:10.1016/j.urolonc.2022.09.012

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

M. J. Reike, M. A. Ingersoll, D. C. Müller, T. C.M. Zuiverloon, T. Strandgaard, A. M. Kamat, S. B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J. P. Sfakianos, J. Meeks, A. Horowitz, P. C. Black

Urology

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

Original language	English (US)
Pages (from-to)	211-218
Number of pages	8
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	41
Issue number	5
DOIs	https://doi.org/10.1016/j.urolonc.2022.09.012
State	Published - May 2023

Keywords

Bacillus Calmette-Guerin (BCG)
Bladder cancer
Immunotherapy

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2022.09.012

Cite this

Reike, M. J., Ingersoll, M. A., Müller, D. C., Zuiverloon, T. C. M., Strandgaard, T., Kamat, A. M., Williams, S. B., Seiler, R., Todenhöfer, T., Dyrskjøt, L., Nawroth, R., Goebell, P., Schmitz-Dräger, B., Sfakianos, J. P., Meeks, J., Horowitz, A., & Black, P. C. (2023). Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. Urologic Oncology: Seminars and Original Investigations, 41(5), 211-218. https://doi.org/10.1016/j.urolonc.2022.09.012

Reike, MJ, Ingersoll, MA, Müller, DC, Zuiverloon, TCM, Strandgaard, T, Kamat, AM, Williams, SB, Seiler, R, Todenhöfer, T, Dyrskjøt, L, Nawroth, R, Goebell, P, Schmitz-Dräger, B, Sfakianos, JP, Meeks, J, Horowitz, A & Black, PC 2023, 'Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III', Urologic Oncology: Seminars and Original Investigations, vol. 41, no. 5, pp. 211-218. https://doi.org/10.1016/j.urolonc.2022.09.012

@article{7006697eae714ba2a969c0cffe820f7c,

title = "Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III",

abstract = "Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.",

keywords = "Bacillus Calmette-Guerin (BCG), Bladder cancer, Immunotherapy",

author = "Reike, {M. J.} and Ingersoll, {M. A.} and M{\"u}ller, {D. C.} and Zuiverloon, {T. C.M.} and T. Strandgaard and Kamat, {A. M.} and Williams, {S. B.} and R. Seiler and T. Todenh{\"o}fer and L. Dyrskj{\o}t and R. Nawroth and P. Goebell and B. Schmitz-Dr{\"a}ger and Sfakianos, {J. P.} and J. Meeks and A. Horowitz and Black, {P. C.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = may,

doi = "10.1016/j.urolonc.2022.09.012",

language = "English (US)",

volume = "41",

pages = "211--218",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

AU - Reike, M. J.

AU - Ingersoll, M. A.

AU - Müller, D. C.

AU - Zuiverloon, T. C.M.

AU - Strandgaard, T.

AU - Kamat, A. M.

AU - Williams, S. B.

AU - Seiler, R.

AU - Todenhöfer, T.

AU - Dyrskjøt, L.

AU - Nawroth, R.

AU - Goebell, P.

AU - Schmitz-Dräger, B.

AU - Sfakianos, J. P.

AU - Meeks, J.

AU - Horowitz, A.

AU - Black, P. C.

PY - 2023/5

Y1 - 2023/5

N2 - Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

AB - Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

KW - Bacillus Calmette-Guerin (BCG)

KW - Bladder cancer

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85140764438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140764438&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2022.09.012

DO - 10.1016/j.urolonc.2022.09.012

M3 - Review article

C2 - 36266219

AN - SCOPUS:85140764438

SN - 1078-1439

VL - 41

SP - 211

EP - 218

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 5

ER -

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this